



Document details

< Back to results | 1 of 1

📄 Export 📄 Download 🖨️ Print ✉️ E-mail 📄 Save to PDF ☆ Add to List More... >

View at Publisher

International Journal of Pharmaceutics
Volume 565, 30 June 2019, Pages 258-268

Targeted drug delivery to the brain via intranasal nanoemulsion : Available proof of concept and existing challenges (Review)

Chatterjee, B.^a ✉️, Gorain, B.^b ✉️, Mohananaidu, K.^a, Sengupta, P.^c ✉️, Mandal, U.K.^d ✉️, Choudhury, H.^e ✉️

^aPharmaceutical Technology, Kulliyah of Pharmacy, International Islamic University Malaysia, Kuantan, 25200, Malaysia

^bSchool of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Selangor 47500, Malaysia

^cNational Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gujarat 382355, India

View additional affiliations ▾

Abstract

▾ View references (98)

Intranasal delivery has shown to circumvent blood-brain-barrier (BBB) and deliver the drugs into the CNS at a higher rate and extent than other conventional routes. The mechanism of drug transport from nose-to-brain is not fully understood yet, but several neuronal pathways are considered to be involved. Intranasal nanoemulsion for brain targeting is investigated extensively. Higher brain distribution of drug after administering intranasal nanoemulsion was established by many researchers. Issues with nasomucosal clearance are solved by formulating modified nanoemulsion; for instance, mucoadhesive nanoemulsion or in situ nanoemulgel. However, no intranasal nanoemulsion for brain targeted drug delivery has been able to cross the way from 'benches to bed-side' of patients. Possibilities of toxicity by repeated administration, irregular nasal absorption during the diseased condition, use of a high amount of surfactants are few of the persisting challenges that need to overcome in coming days. Understanding the ways how current developments has solved some challenges is necessary. At the same time, the future direction of the research on intranasal nanoemulsion should be figured out based on existing challenges. This review is focused on the current developments of intranasal nanoemulsion with special emphasis on the existing challenges that would help to set future research direction. © 2019

SciVal Topic Prominence ⓘ


Topic: Administration, Intranasal | Brain | Nose-to-brain delivery

Prominence percentile: 97.189 ⓘ

Chemistry database information ⓘ

Substances

View all substances (11)



Author keywords

In situ gel | Intranasal | Mucoadhesive nanoemulsion | Nanoemulgel | Nanoemulsion | Nose to brain

Metrics ⓘ View all metrics >

5 Citations in Scopus

1.69 Field-Weighted Citation Impact



PlumX Metrics ▾

Usage, Captures, Mentions, Social Media and Citations beyond Scopus.

Cited by 5 documents

Quantitative estimation of drug permeation through nasal mucosa using in vitro membrane permeability across Calu-3 cell layers for predicting in vivo bioavailability after intranasal administration to rats

Inoue, D., Furubayashi, T., Tanaka, A. (2020) *European Journal of Pharmaceutics and Biopharmaceutics*

Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer's, Parkinson's and Prion's

Nirale, P., Paul, A., Yadav, K.S. (2020) *Life Sciences*

Nanostructured oleic acid/polysorbate 80 emulsions with diminished toxicity in NL-20 cell line: Insights of potential drug carriers

de Lourdes Pérez-González, M.L., González-de la Rosa, C.H., Pérez-Hernández, G. (2020) *Colloids and Surfaces B: Biointerfaces*

View all 5 citing documents

Inform me when this document is cited in Scopus:

Set citation alert >

Set citation feed >

Indexed keywords

EMTREE drug terms: [drug](#) [surfactant](#) [nanoparticle](#)

EMTREE medical terms: [cerebrospinal fluid](#) [drug absorption](#) [drug delivery system](#) [drug formulation](#) [drug targeting](#) [human](#) [lymph vessel](#) [nanoemulsion](#) [nonhuman](#) [priority journal](#) [proof of concept](#) [Review](#) [zeta potential](#) [animal](#) [brain](#) [emulsion](#) [intranasal drug administration](#) [metabolism](#) [nose mucosa](#)

MeSH: [Administration, Intranasal](#) [Animals](#) [Brain](#) [Drug Delivery Systems](#) [Emulsions](#) [Humans](#) [Nanoparticles](#) [Nasal Mucosa](#)

Related documents

Formulation development and evaluation of rotigotine mucoadhesive nanoemulsion for intranasal delivery

Choudhury, H. , Zakaria, N.F.B. , Tilang, P.A.B. (2019) *Journal of Drug Delivery Science and Technology*

Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies

Pires, P.C. , Santos, A.O. (2018) *Journal of Controlled Release*

Preparation and in vitro/ex vivo evaluation of nanoemulsion for transnasal delivery of paliperidone

Patel, M.R. , Patel, M.H. , Patel, R.B. (2016) *Applied Nanoscience (Switzerland)*

View all related documents based on references

Find more related documents in Scopus based on:

[Authors >](#) [Keywords >](#)

Chemicals and CAS Registry Numbers:

Emulsions

Funding details

Funding sponsor	Funding number	Acronym
Ministry of Higher Education, Malaysia	FRGS 17-006-0572	MOHE

Funding text

The authors are thankful to the Ministry of Education, Malaysia (FRGS 17-006-0572) for indirect financial assistance for successful completion of this article. The authors are also thankful to International Islamic University Malaysia and School of Pharmacy, Taylor University, Malaysia for providing some web-based resources for this article.

ISSN: 03785173

CODEN: IJPHD

Source Type: Journal

Original language: English

DOI: 10.1016/j.ijpharm.2019.05.032

PubMed ID: 31095983

Document Type: Review

Publisher: Elsevier B.V.

References (98)

[View in search results format >](#)

All [Export](#) [Print](#) [E-mail](#) [Save to PDF](#) [Create bibliography](#)

View all 98 references

- 1 Abdelbary, G.A., Tadros, M.I.
Brain targeting of olanzapine via intranasal delivery of core-shell difunctional block copolymer mixed nanomicellar carriers: In vitro characterization, ex vivo estimation of nasal toxicity and in vivo biodistribution studies

(2013) *International Journal of Pharmaceutics*, 452 (1-2), pp. 300-310. Cited 65 times.

www.elsevier.com/locate/ijpharm

doi: 10.1016/j.ijpharm.2013.04.084

[View at Publisher](#)